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Abstract
Background: Interventions to improve blood pressure control in hypertension have had limited success in clinical
practice despite evidence of cardiovascular disease prevention in randomised controlled trials.
The objectives of this study were to evaluate blood pressure control and antihypertensive pharmacotherapy pat-
terns in a population of Eastern Central Region of Portugal, attending a hospital outpatient clinic (ambulatory set-
ting) for routine follow-up.
Methods: Medical data of all patients that attended at least two medical appointments of hypertension/
dyslipidemia in a university hospital over a one and a half year period (from January 2008 to June 2009) were
retrospectively analysed. Demographic variables, clinical data and blood pressure values of hypertensive patients
included in the study, as well as prescribing metrics were examined on a descriptive basis and expressed as the
mean ± SD, frequency and percentages. Student’s test and Mann-Whitney rank sum test were used to compare
continuous variables and c
2 test and Fisher exact probability test were used to test for differences between
categorical variables.
Results: In all, 37% of hypertensive patients (n = 76) had their blood pressure controlled according to international
guidelines. About 45.5% of patients with a target blood pressure <140/90 mmHg (n = 156) were controlled,
whereas in patients with diabetes or chronic kidney disease (n = 49) the corresponding figure was only 10.2% (P <
0.001). Among patients initiating hypertension/dyslipidemia consultation within the study period 32.1% had stage 2
hypertension in the first appointment, but this figure decreased to 3.6% in the last consultation (P = 0.012).
Thiazide-type diuretics were the most prescribed antihypertensive drugs (67%) followed by angiotensin receptor
blockers (60%) and beta-blockers (43%). About 95.9% patients with comorbid diabetes were treated with an
angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker.
Conclusions: Clinically important blood pressure decreases can be achieved soon after hypertension medical
appointment initiation. However, many hypertensive patients prescribed with antihypertensive therapy fail to
achieve blood pressure control in clinical practice, this control being worse among patients with diabetes or
chronic kidney disease. As pharmacotherapy patterns seem to coincide with international guidelines, further
research is needed to identify the causes of poor blood pressure control.
Background
Hypertension is a major risk factor in the development
of cardiovascular disease, with myocardial infarction and
stroke being one of the most important health problems
in Portugal causing excess morbidity and mortality [1].
It is estimated that over three million Portuguese adults
(about 30% of the Portuguese population) suffer from
hypertension [2]. In a recently published survey [2], only
11.2% hypertensives had their blood pressure (BP) con-
trolled (<140/90 mmHg). This figure is even lower for
the Central Region of Portugal, where only 9.7% of the
total number of hypertensives have their BP controlled
[2]. Furthermore, of the total number of Portuguese
hypertensives who were aware of having hypertension
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28.9% had their BP controlled. Again, this figure was
lower in the Central Region of Portugal, where the rate
of control was only 26.1%. The definition of controlled
hypertension in this Portuguese survey was considered
as mean systolic BP <140 mmHg and diastolic BP of
<90 mmHg and did not take into account hypertensive
patients with diabetes mellitus or chronic kidney disease
(CKD). The seventh report of the Joint National Com-
mittee on the Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 7) set a lower
BP target (<130/80 mmHg) for hypertensive patients
with diabetes or CKD [3].
The Eastern Central Region of Portugal possesses a
university teaching hospital at Covilhã, named Cova da
Beira Hospital Centre, with an important hypertension/
dyslipidemia outpatient clinic, which serves a significant
hypertensive population of the District of Castelo Branco.
To better understand the unsatisfactory levels of BP con-
trol of this hypertensive population and focus efforts on
improving them, it would be useful to know the extent to
which hypertensive patients with different risk for vascu-
lar complications are not satisfactorily controlled.
Accordingly, a retrospective study was conducted to
evaluate the level of BP control in hypertensive patients,
attending the afore mentioned hypertension/dyslipide-
mia outpatient hospital clinic for routine follow-up,
according to the JNC 7 guidelines (<140/90 mmHg for
general hypertensive patients and <130/80 mmHg for
hypertensive patients with diabetes or CKD).
Methods
Settings
This study was conducted in a hypertension/dyslipide-
mia clinic in the university teaching hospital of Cova da
Beira Hospital Centre, Covilhã, District of Castelo
Branco, located in the Eastern Central Region of Portu-
gal. This outpatient clinic is one of the most important
clinics of this region of Portugal in the field of hyperten-
sion/dyslipidemia and serves a significant hypertensive
population of the Covilhã surrounding area, with a
population of 35,000 inhabitants. It should be empha-
sized that due to a decreased supply of primary care
practitioners in this Region of Portugal that has led to a
shortage in primary care delivery, this outpatient clinic
provides follow-up care to hypertensive patients. This is
done by a health care team composed of internal medi-
cine physicians and nurses. Virtually all hypertensive
patients managed and monitored in this clinic have
essential arterial hypertension.
Study population
The study population consisted of outpatients that
attended the hypertension/dyslipidemia clinic in the
university teaching hospital. All patients are adults aged 18
or over. They were included if they had an established
diagnosis of arterial hypertension (BP measurements in
the clinic of ≥140/90 mmHg) and had attended at least
two medical appointments over a one and a half year per-
iod (from January 2008 to June 2009). Hypertensive
patients without diabetes and/or CKD with BP <140/90
mmHg in their last appointment were considered to have
their BP controlled. For hypertensive patients with dia-
betes or CKD, BP control was defined as BP measure-
ments <130/80 mmHg in their last appointment. Study
subjects were also analyzed based on whether they had
selected “high-risk” conditions or characteristics listed by
JNC 7 as “compelling indications” (i.e., cerebrovascular
disease, CKD, heart failure, ischemic heart disease, dia-
betes) or “special situations” (i.e., obesity, hyperlipidemia,
metabolic syndrome, advanced age) and by stage of hyper-
tension (i.e., Stage 1, 140-159/90-99 mmHg; Stage 2,
≥160/100) [3]. Compelling indications for antihypertensive
drugs are based on benefits from outcome studies or exist-
ing clinical guidelines; the compelling indication is mana-
ged in parallel with the BP [3]. Patients with both
compelling indications and special indications were classi-
fied into the “compelling indications” group. The presence
of these conditions among study subjects was ascertained
based on available diagnostic information, laboratory/
exam values, and treatments/medications recorded any-
time during the study period. BP was measured in a seated
position after a five-minute rest period, using a mercury
sphygmomanometer or semi-automatic device, the mean
of two consecutive measurements being recorded.
Data extraction
Data for this study were retrospectively obtained from the
hospital electronic medical records (HEMR) database.
The HEMR database of Cova da Beira Hospital Centre is
comprised of detailed patient-level clinical and adminis-
trative information from all patients that utilized, at least
once, this hospital. Available information includes patient
demographics, medical problems (including the date on
which each medical problem was first diagnosed), various
measures of physiological status and medications pre-
scribed. Dates for each medical contact are also provided,
allowing all data to be analysed in chronological order.
This database is authorized by the Portugal Department
of Health, the government department responsible for
public health issues and it ensures patient data confiden-
tiality. Since subjects cannot be identified and confidenti-
ality was warranted, institutional review board approval
for this study was neither needed nor sought.
Statistical analysis
Demographic variables, clinical data and BP values of
hypertensive patients included in the study, as well as
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and expressed as the mean ± SD, frequency and percen-
tages. Student’s test and Mann-Whitney rank sum test
were used to compare continuous variables and c
2 test
and Fisher exact probability test were used to test for
differences between categorical variables. For the com-
parison between results in the first and in the last
appointment in the same hypertensive patients who
initiated hypertension consultation within the study per-
iod, the Wilcoxon rank sum test for paired data was
used. All statistical analyses were done using SPSS for
Windows, version 17.0 (SPSS Inc., Chicago, IL) and a P-
value of less than 0.05 was considered to indicate statis-
tical significance.
Results
Patient characteristics
Overall, 273 patients attended medical appointments at
the hypertension/dyslipidemia clinic of Cova da Beira
Hospital Centre for routine follow-up during the study
period. Among these patients, evaluation of 25 patients
was still under course and there wasn’t an established
diagnosis of arterial hypertension and/or dyslipidemia
and 10 patients had a diagnosis of dyslipidemia but not
arterial hypertension. Of the remaining 238 patients, with
an established diagnosis of arterial hypertension, 33 were
excluded from our study because they had only attended
one medical appointment. Most of these patients (n =
27) are no longer followed by the hypertension/dyslipide-
m i ac l i n i cd u et os e v e r a lr e a sons (e.g., referral to other
hospital clinics, residency change to other region served
by a different hospital, renouncement to medical appoint-
ments, death); the remaining 6 hypertensive patients had
been admitted to the hypertension/dyslipidemia clinic
very recently (May or June 2009) and their antihyperten-
sive medication was probably not yet fully titrated. It
should be noted that the first months of antihypertensive
therapy may be a critical period for many patients, espe-
cially for those at the highest risk for adverse outcomes
and several alterations of the therapeutic regimen are
often required to control BP and adverse effects.
Altogether, 205 hypertensive patients satisfied our
inclusion criteria and were included in our statistical
analyses. The overall mean age of these patients was 60
± 12 years, 40.5% being male and 59.5% female (Table
1). Among these patients, 156 (76%) had neither dia-
betes nor CKD and were considered to have a target BP
of <140/90 mmHg, whereas the remaining 49 (24%) had
either diabetes and/or CKD and were considered to be
controlled with a BP of <130/80 mmHg. Mean ages
were 58 ± 12 years for patients without diabetes and
CKD, and 66 ± 10 years for patients with either or both
these pathologies (P < 0.001). There were 37% (58/156)
males in the first group and 51% (25/49) in the second
group (P = 0.085). Most patients were long term hyper-
tensives, with 65% of all patients having high BP for
over five years. Only 8 patients have been diagnosed
hypertensive for the first time within the last twelve
months of the study period.
Thirty-one percent of the study population had a
compelling indication and 52% had a special situation,
as defined by JNC 7. The most common compelling
indications were diabetes (20%), cerebrovascular disease
(8%) and CKD (6%), whereas dyslipidemia (60%),
advanced age (36%) and obesity (24%) were the most
common special situations (Table 1).
The distribution of age-groups and target BP values in
the hypertensive study population are shown in Table 2.
It is worth mentioning that all patients in the age-group
≥18 - <35 years had a BP target value of <140/90
mmHg, and 59.2% patients in the higher cardiovascular
risk group were ≥65 years.
Blood pressure control
Overall, the mean systolic BP of the 205 hypertensive
patients included in our analysis was 140.1 ± 15.0
Table 1 Characteristics of hypertensive patients included
in the study (n = 205)
Characteristics n Frequencies (%)
Age
≥18 - <35 years 4 2.0
35 - 64 years 128 62.4
≥65 years 73 35.6
Gender
Male/Female 83/122 40.5/59.5
Duration of hypertension
<1 year 8 3.9
≥1year and <5 years 83 31.2
≥5 years and <10 years 80 41.5
≥10 years 34 23.4
Comorbid conditions
Cerebrovascular disease 16 7.8
Chronic kidney disease 12 5.9
Diabetes 41 20.0
Heart failure 2 1.0
Ischemic heart disease 8 3.9
Dyslipidemia 122 59.5
Metabolic syndrome 4 2.0
Obesity (body mass index ≥30) 50 24.4
Peripheral arterial disease 5 2.4
Advanced age (≥65 years) 73 35.6
None of the above 35 17.1
Target BP values
(JCN 7 guidelines)
<140/90 mmHg 156 76.1
<130/80 mmHg 49 23.9
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mmHg, with 44% (91/205) patients attaining BP <140/
90 mmHg (Table 3). Among the remaining 56% (114/
205) patients, with a BP equal or higher than 140/90
mmHg, 45% (92/205) patients had stage 1 hypertension
and 11% (22/205) had stage 2 hypertension.
When we consider the target BP values defined by the
JCN 7 guidelines, 45.5% (71/156) patients with neither
diabetes nor CKD attained a BP <140/90 mmHg,
whereas only 10.2% (5/49) patients with diabetes and/or
CKD attained the target value of <130/80 mmHg (<
0.001). In the first group, 45.5% (71/156) patients had
stage 1 hypertension and 9% (14/156) had stage 2 hyper-
tension, according to the JNC 7 classification of BP for
adults. In the second group, 31% (15/49) had their BP
within 120-139/80-89, 43% (21/49) had stage 1 hyper-
tension and 16% (8/49) had stage 2 hypertension. Over-
all, only 37% (76/205) of hypertensive patients had their
BP controlled according to the JCN 7 guidelines. All 5
patients that achieved BP control in the second group
were males, although a significant difference between
sexes was not achieved (P = 0.050). Likewise, the pro-
portion of males in the total of patients that achieved
BP control in the first group (39%, 28/71) was not sig-
nificantly different from the proportion of males in the
total of patients that did not achieve BP control (35%,
30/85, P = 0.594). When considering obese hypertensive
patients (body mass index ≥30), 36.4% (12/33) achieved
BP control in the first group, which is arithmetically
lower, although not significantly (P = 0.232), than the
BP control obtained in nonobese patients (48.0%, 59/
123). In the diabetes and CKD group there was also not
a statistically significant difference (P = 1) in the BP
control between obese (11.8%, 2/17) and nonobese
patients (9.4%, 3/32); however, the number of obese
hypertensive patients in this group was too small to
extract accurate statistical conclusions.
Among patients initiating hypertension consultation
within the study period, 32.1% (9/28) had stage 2 hyper-
tension in the first appointment, but this figure
decreased to 3.6% (1/28) in the last consultation (P =
0.012), and was not significantly different from the
remainder overall population at the last appointment
(11.9%, 21/177, P = 0.322). However, there was a signifi-
cant higher percentage of patients with stage 2 hyper-
tension in the first medical appointment at the
hypertension/dyslipidemia clinic, when compared to the
total study population at the last appointment (P =
0.009). Despite this improvement in BP measures in
patients initiating hypertension consultation within the
study period, there was not a statistically significant (P =
0.188) improvement in the percentage of patients with
controlled BP, according to JNC 7 guidelines, between
the first and the last appointments. However, in these
patients, there was a significant decrease in the mean ±
SD systolic BP from the first to the last appointment
(149.4 ± 17.1 versus 138.1 ± 11.0, P < 0.001). Conver-
sely, the decrease reported in the diastolic BP from the
first to the last appointment was not statistically signifi-
c a n t( 8 7 . 3±1 3 . 2v e r s u s8 3 . 7±9 . 3 ,P = 0.072). The
average interval time between the first and the last
appointment was 6 months in this subgroup of patients,
with an average of 4 medical appointments per patient.
The attainment of BP control per age-group and car-
diovascular risk are represented in Table 2. Concerning
Table 2 Number of patients in each age group/target BP
value combination that achieved BP control
Target BP values
Age <140/90 mmHg <130/80 mmHg
≥18 - <35 years 50% (2/4) patients 0 patients
35 - 64 years 54% (58/108) patients 10% (2/20) patients
≥65 years 25% (11/44) patients 10% (3/29) patients
Table 3 Blood pressure control of hypertensive patients
BP All patients
(n = 205)
Patients with target
BP <140/90 mmHg
(n = 156)
Patients with target
BP <130/80 mmHg
(n = 49)
Patients initiating HT
appointments within
the study period (n =
28) - First appointment
Patients initiating HT
appointments within the
study period (n = 28) -
Last appointment
Mean ± SD SBP/DBP
(mmHg)
140.1 ± 15.0/81.5
± 11.1
138.6 ± 14.4/81.9 ±
10.5
144.6 ± 16.2/80.4 ±
12.9
149.4 ± 17.1/87.3 ± 13.2 138.1 ± 11.0/83.7 ± 9.3
BP <140/90 (mmHg) 91 (44%) 71 (45.5%) 20 (41%) 6 (21%) 11 (39%)
BP ≥140/90 (mmHg) 114 (56%) 85 (54.5%) 29 (59%) 22 (79%) 17 (61%)
BP controlled (JCN 7
guidelines)
76 (37%) 71 (45.5%) 5 (10%) 6 (21.4%) 10 (35.7%)
BP not controlled
120-139/80-89 15 (7%) NA 15 (31%) 0 1 (3.6%)
Stage 1 92 (45%) 71 (45.5%) 21 (43%) 13 (46.4%) 16 (57.1%)
Stage 2 22 (11%) 14 (9%) 8 (16%) 9 (32.1%) 1 (3.6%)
DBP - Diastolic BP; HT - Hypertension; NA - Not applicable; SBP - Systolic BP.
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patients achieving BP control was not significantly dif-
ferent (P = 1) in the age groups ≥18 - <35 years (50%)
and 35-64 years (54%), but was significantly lower (P =
0.001) in the age group ≥65 years (25%). When consid-
ering the higher cardiovascular risk group, the percen-
tage of patients achieving BP control was only 10% for
both age groups involved.
Antihypertensive therapy
In all, 196 patients were prescribed with antihyperten-
sive medication. The remaining 9 patients have only
been counselled to adopt lifestyle modifications in order
to control their BP, and 6 of these were already con-
trolled without any antihypertensive medication. It is
worth noting that these 9 patients were significantly
younger than the average population, with an overall
mean age of 44 ± 13 years (P < 0.001). The recom-
mended lifestyle changes for BP control were in accor-
dance with the JNC 7 guidelines and included:
(1) weight loss in the overweight patients, (2) reduced
sodium intake, (3) increased physical activity, and
(4) limited alcohol consumption.
Overall, the patients took a mean ± SD of 2.7 ± 1.4
antihypertensives daily. Thiazide-type diuretics were the
most frequently prescribed antihypertensive agents, with
a total of 66.8% (137/205) patients being prescribed with
this class of drugs, followed by angiotensin receptor
blockers (ARBs) (60.1%, 123/205) and beta-blockers
(42.6%, 87/205). These three classes of antihypertensives
were the most prescribed (and in the same ranking
order) both in patients without diabetes and/or CKD
and in patients with these diseases (Table 4). However,
the first group took 2.5 ± 1.3 antihypertensives daily,
whereas in the second group this figure was 3.2 ± 1.3
(P = 0.005).
The number of antihypertensive drugs taken per
patient ranged from 1 to 6 (Figure 1). The percentage of
patients taking 1 or 2 antihypertensive drugs were
higher in hypertensives with a target BP of <140/90
mmHg; on the contrary, the percentage of patients tak-
ing 3, 4, 5 or 6 antihypertensive drugs were higher in
patients with a lower target BP (<130/80 mmHg).
As shown in Figure 2, the rate of BP normalization
seemed to be inversely related to the intensity of the
treatment: in patients prescribed with antihypertensives,
the higher the number of drugs, the lower the rate of
BP normalization, with a significant correlation between
the two variables. In patients with target values of <140/
90 mmHg the correlation between those variables was
-0.916 (P = 0.010), and in patients with target values of
<130/80 mmHg the correlation was -0.935 (P =0 . 0 0 6 ) .
It should be noted that in the first group of patients
BP control was not achieved only with a 6-drug
combination regimen therapy, whereas in the second
g r o u pi tw a sn o ta c h i e v e dw i t h4 - ,5 -o r6 - d r u gc o m b i -
nations (Figures 1 and 2). Resistant hypertension must
be strongly suspected at least in 4 patients in whom BP
control was not achieved even with a 6-drug combina-
tion therapy.
For patients without compelling indications, beta-
blockers were the most frequently prescribed anti-
hypertensive agents as monotherapy; for those with
compelling indications angiotensin-converting enzyme
inhibitors (ACEIs) were the most frequently prescribed.
In all, the most common 2-drug combinations were
thiazide diuretic plus ARB (37% of all patients receiving
2 drugs) and thiazide diuretic plus ACEI (22% of all
patients receiving 2 drugs). These 2-drug combinations
were the most common both in patients without or
with compelling indications.
Almost all patients with comorbid diabetes (95.9%)
were treated with an ACEI or ARB, according to the
best practice recommendations; also, according to best
practice, the two reported hypertensive patients (100%)
with comorbid congestive heart failure were treated with
ACEI, ARB, or beta-blocker; however, only one patient
(25%) with a history of myocardial infarction was treated
with beta-blockers.
Discussion
The results presented in this study describe the demo-
graphic and clinical characteristics of hypertensive
patients attending the medical consultation of hyperten-
sion/dyslipidemia in a university teaching hospital
located in the Eastern Central Region of Portugal for
routine follow-up, focusing on the level of hypertension
control and antihypertensive therapy.
According to a survey conducted in 2003 [2], of the
total number of hypertensives in the Central Region of
Portugal who reported taking their medication regularly,
only 26.1% had their BP measurements <140/90 mmHg,
which is significantly smaller than the 44.4% obtained in
our study (Table 3). This difference possibly points to
an improved current care of the hypertensives included
in our study when compared to those included in the
above mentioned survey. Increased awareness of hyper-
tension and the importance of lower BP may have
prompted Portuguese providers and patients to more
aggressively treat high BP, especially after the publica-
tion of the JNC 7 report in 2003. Till now there has
been no data about the percentage of treated hyperten-
sives in clinical practice, in this Portuguese region, with
their BP controlled according to the JNC 7 guidelines.
Our study revealed that 37.1% of hypertensive patients
had their BP controlled according to those guidelines,
with the percentage of patients without diabetes or
CKD attaining BP control (45.5%) significantly higher
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Antihypertensive Drug All patients (n = 205)
(%)
Patients with target
BP <140/90 mmHg
(n = 156) (%)
Patients with target
BP <130/80 mmHg
(n = 49) (%)
P Value*
Loop diuretics 13.2 11.5 18.4 0.218
Furosemide 13.2 11.5 18.4
Thiazide diuretics 66.8 64.1 75.5 0.139
Altizide 1.0 0.6 2.0
Hydrochlorothiazide 50.7 46.8 63.3
Indapamide 15.1 16.7 10.2
Potassium-sparing diuretics 3.9 1.3 12.3 0.003
Spironolactone 2.9 1.3 8.2
Triamterene 1.0 0.0 4.1
Renin inhibitor 2.0 1.9 2.0 1
Aliskiren 2.0 1.9 2.0
Angiotensin-converting enzyme inhibitors 29.8 27.5 36.8 0.221
Cilazapril 1.0 1.3 0.0
Enalapril 11.7 7.7 24.5
Imidapril 0.5 0.6 0.0
Lisinopril 3.4 3.2 4.1
Perindopril 6.8 9.0 0.0
Ramipril 5.9 5.1 8.2
Trandolapril 0.5 0.6 0.0
Angiotensin II-receptor antagonists 60.1 58.4 65.3 0.383
Candesartan 6.3 7.7 2.0
Eprosartan 2.0 1.3 4.1
Irbesartan 8.8 8.3 10.2
Losartan 12.2 13.5 8.2
Olmesartan 2.0 2.6 0.0
Telmisartan 15.1 13.5 20.4
Valsartan 13.7 11.5 20.4
Calcium channel blockers 39.7 36.4 48.9 0.121
Amlodipine 21.5 18.6 30.6
Felodipine 2.0 1.9 2.0
Lercanidipine 3.9 3.8 4.1
Nifedipine 5.4 5.1 6.1
Nimodipine 0.5 0.6 0.0
Nitrendipine 1.0 1.3 0.0
Diltiazem 5.4 5.1 6.1
Beta-blockers 42.6 41.6 45.0 0.689
Atenolol 5.9 6.4 4.1
Bisoprolol 5.9 6.4 4.1
Metoprolol 0.5 0.6 0.0
Nebivolol 23.9 21.2 32.7
Propranolol 0.5 0.6 0.0
Carvedilol 5.9 6.4 4.1
Central alpha-2 agonists 10.8 10.8 10.2 0.888
Clonidine 0.5 0.6 0.0
Methyldopa 0.5 0.6 0.0
Rilmenidine 9.8 9.6 10.2
*P values are for comparison between the two last columns.
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with diabetes or CKD (10.2%). It should be noted that
the reported levels of BP control can vary greatly
depending on the study population, methods and time
frame [4,5]. For example, in one study based on data
from the US National Health and Nutrition Examination
Survey 2003-2004, the BP control rate (to <140/90
mmHg) was 56.6% in treated hypertensives, and 37.5%
in treated hypertensive persons with diabetes mellitus
(for whom the goal BP is <130/80 mmHg) [6]. In a
regional survey performed in the middle-West of France
and involving 1050 treated hypertensives, Ragot et al.
reported that 39% of patients had BP figures <140/90
mmHg and only 13% of the diabetic population were
normalized according to the international recommenda-
tions (<130/80 mmHg) [7]. In a more recent retrospec-
tive observational study conducted in the United States,
Jackson et al. [5] reported a BP control of 49.3% in an
after-JNC 7 cohort. In this cohort, a significantly higher
percentage of nondiabetic patients achieved BP control
compared with those with comorbid diabetes (60.9%
versus 29.4%). Similarly, Andros et al. [8] conducted a
retrospective observational study of BP control in an
insured diabetic population, obtaining a BP control rate
(defined by JNC 7) of 28%, similar to the 29.4% obtained
by Jackson et al. [5]. The results obtained in our study
are less optimistic, especially when considering the per-
centage of BP control attained by hypertensives with
diabetes or CKD (10.2%) and seem to be similar to
those obtained by Ragot et al. in a French population
[7]. The percentage of patients taking a higher number
of antihypertensive drugs were higher in patients with a
lower target BP (<130/80 mmHg) (Figure 1), suggesting
that an effort is being made to further lower BP in this
hypertensive subgroup. However, our results insinuate
that prescribers may not be fully following the JNC 7
recommended BP targets, especially those related to
hypertensives with diabetes or CKD, because the above
mentioned studies demonstrated that it is possible
to obtain a higher BP control in this hypertensive
Figure 1 Number of antihypertensive medications per patient.
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ence in the percentage of hypertensives in each cohort
that achieved a BP of <140/90 mmHg (45.5% versus
40.8%; P = 0.564). Thus, our findings indicate that
patients who would benefit most from tighter control of
BP, especially those with compelling indications,
appeared to do worse than those with uncomplicated
hypertension. Furthermore, it seems to us that stage 1
hypertension is not seen as a major problem because a
rather significant percentage of hypertensive patients is
maintained in this hypertension stage (Table 3). Other
possible underlying causes of poor BP control are guide-
lines unawareness and therapeutic inertia on the part of
providers and poor adherence and persistence with pre-
scribed medications and lifestyle modifications by
patients. Results of studies suggest that antihypertensive
medications are frequently not intensified when BP
remains uncontrolled, termed clinical inertia [9-11]. In
the recent Harris Survey [12], more than 30% of hyper-
tensive patients reported that their medication was not
changed or increased despite the fact that their BP was
still >140/90 mmHg. Antihypertensive medication non-
adherence is another major factor that must be thought
about when considering the possible reasons for the
inadequate BP control. Indeed, there is a large propor-
tion of patients in our study (65%) who had hyperten-
s i o nf o ro v e rf i v ey e a r s .I ti sk n o w nt h a tp a t i e n t
persistence with prescribed therapy for any chronic dis-
ease typically declines over time, and hypertension is no
exception [13-15].
Of particular note is that the BP control rate in
patients with target values of <140/90 mmHg was signif-
icantly lower in older hypertensive individuals (25%;
Table 2), which is in accordance with rates mentioned
in the literature and are largely due to poor control of
systolic BP [3,16]. Obesity is identified as one cause of
resistant hypertension [17] and there was a trend, albeit
not significant, toward higher BP control between non-
obese hypertensive patients (40% vs 28%, 0.127). The
nonsignificant difference in BP control rate between
Figure 2 Blood pressure normalization according to the number of antihypertensive drugs.
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the limited sample size, because >75% of the patients
with diagnosed arterial hypertension were nonobese
(body mass index <30).
The differences in rates of BP control between males
and females were not significant in the <140/90 mmHg
and in the <130/80 mmHg BP targeted population. Our
results are in accordance with a recent study assessing
gender difference in BP control that used the same cut
points of uncontrolled BP defined by the JNC 7 [18].
Our results also indicate that there is a significantly
higher percentage of patients with stage 2 hypertension
in the first medical appointment at the hypertension/
dyslipidemia clinic, when compared to the same patients
and to the total study population at the last medical
appointment. The decrease in stage 2 hypertension in
patients attending the hypertension/dyslipidemia clinic
for the first time was paralleled by a significant decrease
in the systolic BP from the first to the last appointment
(from 149.4 ± 17.1 to 138.1 ± 11.0, P <0 . 0 0 1 ) .T h e s e
facts suggest that clinically important BP decreases can
be achieved soon after hypertension medical appoint-
ment initiation.
Results from this study indicate that prescribers are
following the JNC 7 drug therapy recommendations,
including the use of thiazide-type diuretics as preferred
initial agent in patients without compelling indications
and those related to compelling indications. In fact, the
use of ACEIs and ARBs in patients with diabetes and/or
congestive heart failure coincides with JNC 7 recom-
mendations. Data reported here do not, however, sug-
gest that postmyocardial infarction patients are being
mostly treated with beta-blockers.
The observed relationship between increased number
of antihypertensive drugs and poorer BP control (Figure
2) could be explained by the fact that patients whose BP
is more difficult to control are likely to be treated with
multiple drugs. Thus, this measurement may be a conse-
quence of poor BP control.
Several features of our study deserve further comment.
First, the objective of this study was to describe levels of
BP control in subgroups of hypertensive patients defined
on the basis of important characteristics, and not to
directly compare such levels across subgroups. For this
motive, analyses adjusted for other characteristics were
not conducted. Second, apart from patients initiating
hypertension appointments within the study period, in
which the BP measurements in the first appointment
was also considered, BP control was determined based
on the last available readings during the retrospective
study period. These measurements may or may not be
representative of the adequacy of control over the entire
corresponding period. Third, drug information in the
study database is confined to prescriptions written and
not necessarily to those dispensed or used. Whether
written prescriptions were filled by the patients and the
level of medication adherence among patients who did
fill the prescriptions is unknown. Finally, because of the
retrospective design of the study, some data were not
available or not able to be validated during the data col-
lection process (Table 1). Although the missing data
were quite reduced, the possibility exists that certain
patient characteristics, conditions and risk factors were
over- or under-represented.
Conclusions
The findings of this study indicate that many treated
hypertensive patients fail to achieve BP control accord-
ing to the JNC 7 guidelines. The most troublesome
result, however, is the extremely low BP control rate
attained by hypertensives with diabetes or CKD, i.e., BP
control is worse among patients who are at high risk for
adverse outcomes and may benefit the most from lower
BP levels. The results obtained in this hypertensive sub-
population are significantly worse than those obtained
by other authors. Even the BP control in hypertensives
without diabetes or CKD can be improved if we com-
pare our results with those obtained in clinical practice
in other countries. Additional research is needed to
identify the underlying causes of poor BP control, such
as guidelines unawareness and therapeutic inertia on the
part of providers and poor adherence and persistence
with prescribed medications and lifestyle modifications
by patients, so that team-based health care providers
and patient interventions can be established that may
address these causes.
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